[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568404":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer Patients",null,"All patients with stomach and esophageal malignancies referred for chemotherapy of the outpatient clinic at the department of Medical Oncology at the Erasmus University Medical Center.",[13],"Device: Proactive Monitoring",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Proactive Monitoring","Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jason den Duijn, MSc.","CONTACT","+31107040704","j.denduijn@erasmusmc.nl",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Erasmus University Medical Center","RECRUITING","Rotterdam","South Holland","3015GD","Netherlands",{"type":35,"coordinates":36},"Point",[37,38],4.47917,51.9225,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jason den Duijn","Principal Investigator","100568404",false,"NCT06680778","Pro-active Monitoring of Vital Signs in Oncology Patients Using a Smartwatch","The Use of Proa-active Monitoring by Measuring Vital Signs Using a Fitbit for a 3-month Period Before, During, and After Chemotherapy in Patients With Cancer","PROGRESS","Inclusion Criteria:\n\n* Age ≥18 years;\n* Diagnosis of stomach or esophageal cancer with an indication of starting chemotherapy\n* Knowledge how to handle a Fitbit\n* Mastery of Dutch language\n* Able and willing to give written informed consent\n\nExclusion Criteria:\n\n* Cognitive disorders or severe emotional instability\n* Already participating in an exercise trial","ALL","18 Years",{"count":56,"type":57},175,"ESTIMATED","OBSERVATIONAL","The goal of this single center prospective observational study is to determine the effect of chemotherapy on (the change in) vital parameters. The main question it aims to answer are: Can changes in vital parameters be measured by using a Fitbit in patients with cancer while undergoing chemotherapy. Participants will be asked to wear a Fitbit for the first two cycles of chemotherapy to evaluate the changes in vital parameters.",[61,62],"Cancer","Emergencies",[64,65,66],"cancer","monitoring","Fitbit","2025-08-12",{"date":69,"type":70},"2025-08-13","ACTUAL",{"date":72,"type":70},"2025-07-01",{"date":74,"type":57},"2025-12-31",{"name":5,"class":6},1]